The modified compound bound to the same serotonin receptors as DMT, but in a slightly different manner. Thus, a research team led by Dr. David Olson at the University of California, Davis set out to design a drug that retained LSD’s ability to promote neuron growth without the hallucinogenic potential. Results of their effort, which was funded in part by NIH, appeared in Proceedings of the National Academy of Sciences on April 14, 2025. Federal funding on psychedelics would remain dry for 50 years, until 2021 when Johns Hopkins University (Baltimore) was awarded a nearly $4 million NIH grant to investigate the potential effects of psilocybin on tobacco addiction.
NIDA, NIMH Directors Describe Promise, Challenges Associated With Psychedelics Research
That means there is very little literature available on these compounds, so user experiences on Erowid can provide a helpful steer for medical professionals. Among Erowid’s many citations are studies into the effects of new “research chemicals”, the grey-area-legal “designer drugs” that number in their thousands. Thirty years ago, drug users flocked to a website called Erowid to describe experiences on everything from Advil to LSD.
Psychedelic Drugs
“Erowid is one of the few websites where emergency workers or doctors can find information on new substances,” says Nicolas Langlitz, a professor of anthropologist at the New School for Social Research in New York City. “Erowid serves as a substitute for scientific research,” he says, adding that some scraps of toxicology data may be available elsewhere but, as far as effects psychedelic and dissociative drugs nida on humans go, Erowid’s a goldmine. Davis and others say Erowid’s large-scale data-led approach made the website a useful repository for all sorts of information that would find their way into official assessments on toxicology, interactions between drugs or even just molecular breakdowns of chemical compounds. Back in 1995, when Erowid was founded, psychedelics were very much of the underground. This was a hostile time for drug reform, just over a decade since US president Ronald Reagan had expanded the war on drugs.
Centers for Disease Controls and Prevention (CDC), some commercial products such as candies marketed as containing psilocybin have also been found to contain toxic chemicals and have caused severe illness. Among people aged 12 or older in 2021, 2.6% (or about 7.4 million people) reported using hallucinogens in the past 12 months. BBC Click visits CES 2025 to find out about the latest health tech, from medical tools to well-being devices. “And I’ve found it invaluable, especially at a time when there were no resources other than the underground. That’s enabled a lot of science.”
The researchers developed a procedure for synthesizing the compound, which they named JRT, from commercially available starting materials. Joking that his opinion was his own and should be subject to editorial review, he speculated that ketamine helped relaunch psychedelic medicine by defining a pathway for other high-risk, high-reward research. Learn more about clinical research and how to participate in a NIDA-funded or NIDA-conducted clinical trial.
Should you always treat a fever?
Differentiating Erowid from the others was a “respect for information, which really did change the psychedelic subculture, remarkably, in the ’90s and 2000s”. Today, researchers are seeing a surge of clinical trials nationwide using psychedelic drugs such as psilocybin and LSD, according to David Goldman, Clinical Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). MDMA (an abbreviation of 3,4-methylenedioxymethamphetamine), also called “Molly” or “Ecstasy,” is a lab-made (synthetic) drug that has effects similar to stimulants like methamphetamine. It is typically sold illicitly as colorful tablets with imprinted logos, capsules, powder, or liquid.
While short-term positive and negative mood changes are common with psychedelic and dissociative drugs, more research is needed to better understand the long-term effects these substances may have on mental health. They must assess the role of set and setting and the importance of the psychedelic or mystical experience that may accompany use of the drugs. Today, the psychedelic science industry is reportedly worth $3bn (£2.25bn) and only growing. Today, the social stigma around some types of drug use has softened to the point that Ayahuasca ceremonies, mushrooms and ketamine have even become a fixture in some corners of the business world. While these substances are still illegal in many countries, a growing number of places are choosing to decriminalise drugs that were previously subject to extensive crack downs. In recent years, psychedelics have also gathered renewed interest from the scientific community as a potential approach for treating conditions such as post-traumatic stress disorder.
Share or Embed This Item
- The institute also supports clinical investigations into psilocybin as a therapeutic substance.
- Researchers are also investigating other drugs sometimes classified as psychedelic and dissociative drugs, such as MDMA, and the way they work in the brain.
- See NIDA-funded projects related to psychedelic and dissociative drugs, and learn more about related clinical trials.
- The modified compound bound to the same serotonin receptors as DMT, but in a slightly different manner.
- Increasing the number of people achieving long-term recovery from SUDs is a national policy priority and a major goal of…
MDMA first became popular in nightclubs, but people now take it in a wide range of settings. Researchers are also studying MDMA as a treatment for depression and post-traumatic stress disorder (PTSD) in supervised clinical research trials. Research to date suggests that use of psilocybin does not typically lead to addiction.2,18 To be diagnosed with a substance use disorder, a person must meet specific diagnostic criteria for continued substance use despite negative consequences. NIDA supports and conducts research to learn whether some of these drugs may help treat substance use disorders in medical settings.
What is psychedelic-assisted therapy?
- These include studies on its effectiveness and safety as a treatment for substance use disorders and to help people quit smoking.
- More studies are needed to better understand how psychedelic and dissociative drugs work.
- This resulted in a compound that had the same 3D structure as LSD but altered the way it bound to its target receptor, similar to the modified DMT.
“Although existing pharmacologic treatments such as antidepressants and medications for opioid use disorder are valuable for many people with these conditions, a large proportion are not helped by those treatments. … Psychedelic drugs represent a promising psychotherapeutic frontier,” they wrote. A typical approach is to administer these drugs in one to three sessions, combined with counseling, in a relaxing setting designed to help the patient be receptive to new perceptions, thoughts, and feelings, including mystical-type experiences.
Altered Perception
Though more research is needed, scientists theorize that these substances promote brain changes that have the potential to promote healthy thought patterns,13 potentially supporting the effectiveness of talk therapy. NIDA is conducting and supporting preclinical (laboratory) research into psilocybin’s effects on the brain and body, and whether there are similar substances that may have the same benefits without side-effects such as hallucinations. The institute also supports clinical investigations into psilocybin as a therapeutic substance. These include studies on its effectiveness and safety as a treatment for substance use disorders and to help people quit smoking. More studies are needed to better understand how psychedelic and dissociative drugs work. While researchers debate how to describe these drugs and how specific drugs should be classified, they generally group them according to what is known about how they work in the brain.
Among people aged 12 or older in 2020, 0.2% (or about 493,000 people) had a hallucinogen use disorder in the past 12 months.
He discussed pitfalls in clinical trials with psychedelic drugs, including the importance of concurrent psychotherapy, expectancy, and placebo effects, and the peculiar problem that participants who do not receive the expected drug can react negatively, a phenomenon known as nocebo effect. Information on the use of psychedelic and dissociative drugs is collected by several national surveys. These surveys use the terms “hallucinogen” and “hallucinogen use disorder” and data from those surveys are reported below. Previous research showed that modification of a psychedelic drug called N,N-dimethyltryptamine (DMT) could reduce its hallucinogenic potential while retaining its ability to promote plasticity.